Clinical trials: Type 2 Diabetic
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Among adult individuals with type 2 diabetes mellitus and at risk for heart failure with impaired relaxation of the heart mildly reduced kidney filtration function (Type 4 cardiorenal syndrome) this trial will evaluate the…
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
- Trial name
- NCT02251431
- Testing
- BYDUREON
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Baylor Research Institute
Tooth Replacement
Dental Implant Study Comparing Two Types of Metals Used for Dental Implants
The purpose of this research study is to compare the healing differences of two metals (trabecular vs. standard titanium) that are used for dental implants.
- Trial name
- ZMU (NCT01714024)
- Testing
- Zimmer Trabecular Metal Test Cylinder, Zimmer Titanium Test Cylinder
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Diabetes Mellitus, Type 2
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus.
- Trial name
- NCT01703286
- Testing
- Linagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Insulin Glargine Versus Twice-Daily NPH
To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.
- Trial name
- NCT00687453
- Testing
- Insulin glargine at bedtime instead of NPH, NPH twice-daily
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Charles Drew University of Medicine and Science
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263
- Trial name
- NCT01128621
- Testing
- GSK1292263, Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome
The investigators are examining the activation of insulin signaling factors in skeletal muscles of human diabetics. The investigators are characterizing the defects in signaling, and are examining the effects of anti-diabetic…
- Trial name
- NCT00690755
- Where
- United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes
DIabetic Retinopathy Candesartan Trials
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normoalbuminuric type 2 diabetic patients with retinopathy.
- Trial name
- DIRECT (NCT00252694)
- Testing
- candesartan
- Volunteers
- 4,717 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes
to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue
- Trial name
- NCT00332488
- Testing
- Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin
- Where
- 120 sites in United States, Argentina and 9 more
- Volunteers
- 547 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Hypogonadotropic Hypogonadism, Type 2 Diabetes
Hypogonadism in Young Men With Type 2 Diabetes
Low testosterone production, known clinically as hypogonadism, appears to be common complication of type 2 diabetes, affecting one in three diabetic men.
- Trial name
- NCT01155518
- Testing
- testosterone, clomiphene
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- State University of New York at Buffalo
Diabetes Mellitus Type 2
Home Exercise to Enhance Mobility for Older Diabetics
The goal of the proposed research is to test whether a long-term exercise program in sedentary Veterans with diabetes will produce sustained improvement in mobility performance and physical activity.
- Trial name
- NCT01308008
- Testing
- home exercise/physical activity (PA) enhancement program with behavioral support, flex and toning health education program
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- VA Office of Research and Development
Diabetic Macular Edema
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema
- Trial name
- NCT00768040
- Testing
- Aliskiren
- Where
- 12 sites in United States, Denmark
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (Linagliptin) (5 mg / once daily) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg…
- Trial name
- NCT00641043
- Testing
- Linagliptin + pioglitazone (30 mg)
- Where
- 43 sites in Austria, Greece and 5 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Supplements containing goldenseal, a perennial herb native to North America, have consistently ranked among the top 20 highest selling natural products throughout the last decade.
- Trial name
- NCT05081583
- Testing
- Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington State University
Type 2 Diabetes
Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells.
- Trial name
- NCT00609154
- Testing
- glucagon like peptide-1, glucose control
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Diabetes Mellitus, Type 2
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
Efficacy of BI 1356 compared to placebo in patients for whom metformin therapy is inappropriate (intolerability, contraindication).
- Trial name
- NCT00740051
- Testing
- Linagliptin, Glimepiride
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 227 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathy
Effect of Sulodexide in Early Diabetic Nephropathy
The purpose of the study is to determine whether treatment with sulodexide is effective in reducing the level of urine albumin excretion in patients with early diabetic kidney disease expressed as microalbuminuria.
- Trial name
- NCT00130208
- Testing
- Sulodexide
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 1,056 people
- Sponsor
- Keryx Biopharmaceuticals
Diabetic Nephropathy
Nephropathy In Type 2 Diabetes and Cardio-renal Events
The NID-2 study, a multicentric study (21 centres enrolled), was planned in two phases: Phase 1(observational study, completed in September 2005): after the identification of a type-2 diabetic population with typical Diabetic…
- Trial name
- NID-2 (NCT00535925)
- Testing
- SoC therapy, irbesartan, ramipril
- Where
- Italy
- Volunteers
- 850 people
- Sponsor
- University of Campania Luigi Vanvitelli
Type 2 Diabetes Mellitus
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet…
- Trial name
- NCT00367055
- Testing
- rosiglitazone-metformin, Metformin, metformin+ gliclazide
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Diabetes, Type I, Diabetes, Type II
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Coronary vascular dysfunction is highly prevalent among patients with known or suspected Coronary Artery Disease (CAD)1, increases the severity of inducible myocardial ischemia (beyond the effects of upstream coronary…
- Conditions
- Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
- Trial name
- RAND-CFR (NCT01754259)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Brigham and Women's Hospital